In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors —are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen.

CAR T cells use the scFv domain of the CAR to recognize and bind to the tumor-associated antigen (TAA) on the tumor cell surface. This binding activates CAR T cells signaling...

The chimeric antigen receptor (CAR) on CAR-T cells is a hybrid of the antigen-recognition region of an antibody combined with the underlying machinery of a T cell (Figure 1.2). To understand the CAR, it is necessary to first understand the structure of antibodies and TCRs.

2021年8月3日 · CARs are synthetic receptors meant to direct T cells to specific targets, for this reason, they contain an antigen-binding domain and hinge on the extracellular space, a transmembrane domain responsible for anchoring both to the cellular membrane, and an endoplasmic domain designed to trigger a signaling cascade, fundamental for CAR-T cell ...

After isolating T cells from the peripheral blood of the patient (autologous T cells, above) or a healthy donor (allogeneic T cells, below), CAR genes are engineered into T cells...

3 天之前 · Chimeric antigen receptor (CAR) T cell therapy was pioneered in the 1990s, and its clinical success in treating refractory hematological malignancies established it as a promising cancer immunotherapy. 1, 2, 3 In addition to T cells, alternative immune cells such as natural killer (NK) cells, invariant NK T cells, γδ T cells, and macrophages have …

2020年5月25日 · Several decades of research have delineated the mechanism of TCR signal transduction and its impact on T cell performance. This knowledge provides the foundation for chimeric antigen receptor T...

2022年4月28日 · Chimeric Antigen Receptor (CAR) T-cell therapy represents a major advance in the treatment of hematologic malignancies, as demonstrated by the high response rates and...

2020年8月1日 · Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies have significant clinical efficacy in treating CD19-positive B cell cancers.

2018年3月15日 · CAR-T cell therapy involves genetically engineering T cells to express chimeric antigen receptors (CARs) that target specific tumor antigens. CARs consist of an antigen recognition domain from an antibody fused to T cell signaling domains.